196 related articles for article (PubMed ID: 8879780)
1. Randomized comparison of amphotericin B deoxycholate dissolved in dextrose or Intralipid for the treatment of AIDS-associated cryptococcal meningitis.
Joly V; Aubry P; Ndayiragide A; Carrière I; Kawa E; Mlika-Cabanne N; Aboulker JP; Coulaud JP; Larouze B; Yeni P
Clin Infect Dis; 1996 Sep; 23(3):556-62. PubMed ID: 8879780
[TBL] [Abstract][Full Text] [Related]
2. Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis: a randomized, double-blind clinical trial of efficacy and safety.
Hamill RJ; Sobel JD; El-Sadr W; Johnson PC; Graybill JR; Javaly K; Barker DE
Clin Infect Dis; 2010 Jul; 51(2):225-32. PubMed ID: 20536366
[TBL] [Abstract][Full Text] [Related]
3. Trial of glucose versus fat emulsion in preparation of amphotericin for use in HIV infected patients with candidiasis.
Chavanet PY; Garry I; Charlier N; Caillot D; Kisterman JP; D'Athis M; Portier H
BMJ; 1992 Oct; 305(6859):921-5. PubMed ID: 1458072
[TBL] [Abstract][Full Text] [Related]
4. A retrospective study on the efficacy and safety of amphotericin B in a lipid emulsion for the treatment of cryptococcal meningitis in AIDS patients.
Torre D; Banfi G; Tambini R; Speranza F; Zeroli C; Martegani R; Airoldi M; Fiori G
J Infect; 1998 Jul; 37(1):36-8. PubMed ID: 9733375
[TBL] [Abstract][Full Text] [Related]
5. Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis.
Leenders AC; Reiss P; Portegies P; Clezy K; Hop WC; Hoy J; Borleffs JC; Allworth T; Kauffmann RH; Jones P; Kroon FP; Verbrugh HA; de Marie S
AIDS; 1997 Oct; 11(12):1463-71. PubMed ID: 9342068
[TBL] [Abstract][Full Text] [Related]
6. Continuous infusion of amphotericin B deoxycholate in the treatment of cryptococcal meningoencephalitis: analysis of safety and fungicidal activity.
Falci DR; Lunardi LW; Ramos CG; Bay MB; Aquino VR; Goldani LZ
Clin Infect Dis; 2010 Mar; 50(5):e26-9. PubMed ID: 20121575
[TBL] [Abstract][Full Text] [Related]
7. Alternate-day versus once-daily administration of amphotericin B in the treatment of cryptococcal meningitis: a randomized controlled trial.
Techapornroong M; Suankratay C
Scand J Infect Dis; 2007; 39(10):896-901. PubMed ID: 17852947
[TBL] [Abstract][Full Text] [Related]
8. Amphotericin B in a lipid emulsion for the treatment of cryptococcal meningitis in AIDS patients.
Joly V; Geoffray C; Reynes J; Goujard C; Méchali D; Maslo C; Raffi F; Yeni P
J Antimicrob Chemother; 1996 Jul; 38(1):117-26. PubMed ID: 8858463
[TBL] [Abstract][Full Text] [Related]
9. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group.
van der Horst CM; Saag MS; Cloud GA; Hamill RJ; Graybill JR; Sobel JD; Johnson PC; Tuazon CU; Kerkering T; Moskovitz BL; Powderly WG; Dismukes WE
N Engl J Med; 1997 Jul; 337(1):15-21. PubMed ID: 9203426
[TBL] [Abstract][Full Text] [Related]
10. Management of amphotericin-induced phlebitis among HIV patients with cryptococcal meningitis in a resource-limited setting: a prospective cohort study.
Ahimbisibwe C; Kwizera R; Ndyetukira JF; Kugonza F; Sadiq A; Hullsiek KH; Williams DA; Rhein J; Boulware DR; Meya DB
BMC Infect Dis; 2019 Jun; 19(1):558. PubMed ID: 31242860
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of induction regimens for cryptococcal meningitis in HIV-infected adults: a systematic review and network meta-analysis.
Chen CH; Li H; Chen HM; Chen YM; Chang YJ; Lin PY; Hsu CW; Tseng PT; Lin KH; Tu YK
Sci Rep; 2021 Apr; 11(1):8565. PubMed ID: 33883566
[TBL] [Abstract][Full Text] [Related]
12. British HIV Association opportunistic infection guidelines: in defence of amphotericin B deoxycholate.
Bicanic T; Ogden D; Whitney L; Loyse A; Jarvis J
HIV Med; 2012 Nov; 13(10):636-7. PubMed ID: 23051823
[No Abstract] [Full Text] [Related]
13. Factors associated with early mycological clearance in HIV-associated cryptococcal meningitis.
Concha-Velasco F; González-Lagos E; Seas C; Bustamante B
PLoS One; 2017; 12(3):e0174459. PubMed ID: 28355252
[TBL] [Abstract][Full Text] [Related]
14. Use of intralipid as a vehicle for amphotericin B in the treatment of cryptococcal meningitis in a renal transplant recipient.
Nicol AJ; Cassidy MJ; Michalowsky K; Kahn D
Nephron; 1996; 73(2):312-3. PubMed ID: 8773363
[No Abstract] [Full Text] [Related]
15. Continuously infused amphotericin B deoxycholate for primary treatment of invasive fungal disease in acute myeloid leukaemia.
Rothenbühler C; Held U; Manz MG; Schanz U; Gerber B
Hematol Oncol; 2018 Apr; 36(2):471-480. PubMed ID: 29431860
[TBL] [Abstract][Full Text] [Related]
16. Liposomal amphotericin B (Fungisome) for the treatment of cryptococcal meningitis in HIV/AIDS patients in India: a multicentric, randomized controlled trial.
Jadhav MP; Bamba A; Shinde VM; Gogtay N; Kshirsagar NA; Bichile LS; Mathai D; Sharma A; Varma S; Digumarathi R
J Postgrad Med; 2010; 56(2):71-5. PubMed ID: 20622383
[TBL] [Abstract][Full Text] [Related]
17. Implementation of clinical practice policy on the continuous intravenous administration of amphotericin B deoxycholate.
Maharom P; Thamlikitkul V
J Med Assoc Thai; 2006 Nov; 89 Suppl 5():S118-24. PubMed ID: 17718252
[TBL] [Abstract][Full Text] [Related]
18. A prospective study of AIDS-associated cryptococcal meningitis in Thailand treated with high-dose amphotericin B.
Pitisuttithum P; Tansuphasawadikul S; Simpson AJ; Howe PA; White NJ
J Infect; 2001 Nov; 43(4):226-33. PubMed ID: 11869059
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Intralipid infusion in reducing amphotericin-B-associated nephrotoxicity in head and neck invasive fungal infection: A randomized, controlled trial.
Hasibi M; Jafari S; Manshadi SA; Asadollahi M; Salehi M; Zarch VV; Kouhi A
Ear Nose Throat J; 2017 Feb; 96(2):E18-E22. PubMed ID: 28231371
[TBL] [Abstract][Full Text] [Related]
20. Safety and toxicity of amphotericin B in glucose 5% or intralipid 20% in neutropenic patients with pneumonia or fever of unknown origin: randomised study.
Schöffski P; Freund M; Wunder R; Petersen D; Köhne CH; Hecker H; Schubert U; Ganser A
BMJ; 1998 Aug; 317(7155):379-84. PubMed ID: 9694753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
